ULTRAGENYX COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR DTX401 AAV GENE THERAPY FOR GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)

Reuters · 12/30/2025 21:05

Please log in to view news